Abstract

The precise control of mitochondrial calcium ( m Ca 2+ ) exchange allows the cardiomyocyte to balance the regulation of mitochondrial metabolism against the risk of m Ca 2+ overload and cell death. The mitochondrial sodium-calcium exchanger (NCLX) is a major route of m Ca 2+ efflux and thus is one of the key proteins that govern m Ca 2+ homeostasis. Recent studies have demonstrated that increasing NCLX-dependent m Ca 2+ efflux is a promising therapeutic objective for pathologies characterized by deleterious m Ca 2+ overload such as ischemia-reperfusion injury, heart failure, and neurodegeneration. A substantial barrier to the development of NCLX-based therapies is that no pharmacologic activators of NCLX are currently available, and indeed, very little is known about the fundamental mechanisms that stimulate or inhibit NCLX activity in vivo . Therefore, we generated a plasmid encoding a biotin ligase domain fused to the C-terminus of human NCLX (hNCLX-BioID2HA) and used this construct to perform an in vitro proximity biotinylation screen for the unbiased detection of proteins that interact with NCLX and/or modulate NCLX function. We identified ~120 candidate NCLX-proximal mitochondrial proteins in AC16 cardiomyocytes and ~80 in HeLa cells, including several of unknown function. Twenty-five proteins were detected in both data sets, suggestive of conserved function between these two cell types. Current studies are defining the specific molecular function of these mitochondrial proteins and their effects on NCLX expression, NCLX activity, and overall m Ca 2+ homeostasis. We are also developing a novel NCLX-3xFLAG knock-in mouse model to enable in vivo expression of C-terminal epitope-tagged NCLX under the control of the endogenous murine promoter. We expect this model to aid in overcoming the significant proteomic challenges of manipulating this 13-transmembrane protein. Together, these approaches will help to uncover the post-translational mechanisms that regulate NCLX-dependent m Ca 2+ efflux and to identify new therapeutic targets for heart failure and other diseases characterized by disrupted m Ca 2+ homeostasis.

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.